TWI763972B - 經修飾之脂質化鬆弛素ｂ鏈胜肽及其醫療用途 - Google Patents

經修飾之脂質化鬆弛素ｂ鏈胜肽及其醫療用途

Info

Publication number
TWI763972B
TWI763972B TW108103457A TW108103457A TWI763972B TW I763972 B TWI763972 B TW I763972B TW 108103457 A TW108103457 A TW 108103457A TW 108103457 A TW108103457 A TW 108103457A TW I763972 B TWI763972 B TW I763972B
Authority
TW
Taiwan
Prior art keywords
variants
peptide
acid
amino
xaa
Prior art date
Application number
TW108103457A
Other languages
English (en)
Chinese (zh)
Other versions
TW201940505A (zh
Inventor
艾利維亞 杜克洛
史蒂芬妮 艾里安諾
賽爾吉歐 馬拉特
荷契皮德 克萊爾 米諾萊帝
伊莉莎白 比安奇
拉斐爾 艾格尼托
帕歐拉 馬高堤
阿萊西亞 桑托佩提
Original Assignee
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司
Publication of TW201940505A publication Critical patent/TW201940505A/zh
Application granted granted Critical
Publication of TWI763972B publication Critical patent/TWI763972B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108103457A 2018-01-31 2019-01-31 經修飾之脂質化鬆弛素ｂ鏈胜肽及其醫療用途 TWI763972B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
EP18305094.7 2018-01-31
??18305094.7 2018-01-31

Publications (2)

Publication Number Publication Date
TW201940505A TW201940505A (zh) 2019-10-16
TWI763972B true TWI763972B (zh) 2022-05-11

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108103457A TWI763972B (zh) 2018-01-31 2019-01-31 經修飾之脂質化鬆弛素ｂ鏈胜肽及其醫療用途

Country Status (29)

Country Link
US (3) US10961295B2 (https=)
EP (1) EP3746467B1 (https=)
JP (1) JP7295871B2 (https=)
KR (1) KR102755938B1 (https=)
CN (1) CN111770934B (https=)
AR (1) AR114325A1 (https=)
AU (1) AU2019214358B2 (https=)
BR (1) BR112020014834A2 (https=)
CA (1) CA3089657A1 (https=)
CO (1) CO2020008308A2 (https=)
DK (1) DK3746467T3 (https=)
ES (1) ES3058633T3 (https=)
FI (1) FI3746467T3 (https=)
HR (1) HRP20260016T1 (https=)
IL (2) IL316406A (https=)
LT (1) LT3746467T (https=)
MA (1) MA52994A (https=)
MX (1) MX2020008096A (https=)
MY (1) MY199821A (https=)
NZ (1) NZ766762A (https=)
PH (1) PH12020551118A1 (https=)
PL (1) PL3746467T3 (https=)
PT (1) PT3746467T (https=)
RS (1) RS67606B1 (https=)
SG (1) SG11202006903WA (https=)
SI (1) SI3746467T1 (https=)
TW (1) TWI763972B (https=)
UY (1) UY38069A (https=)
WO (1) WO2019149782A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
KR20260035823A (ko) 2023-05-18 2026-03-13 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157829A1 (en) * 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923283A2 (pt) * 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
EP2726502A1 (en) * 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
US20160152679A1 (en) 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
EP3838285A1 (en) * 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)
CN110637027B (zh) * 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157829A1 (en) * 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides

Also Published As

Publication number Publication date
IL276170B1 (en) 2024-11-01
WO2019149782A1 (en) 2019-08-08
KR102755938B1 (ko) 2025-01-20
UY38069A (es) 2019-08-30
IL316406A (en) 2024-12-01
JP7295871B2 (ja) 2023-06-21
ES3058633T3 (en) 2026-03-12
BR112020014834A2 (pt) 2020-12-08
US20190233494A1 (en) 2019-08-01
CN111770934B (zh) 2024-10-18
TW201940505A (zh) 2019-10-16
KR20200116085A (ko) 2020-10-08
US10961295B2 (en) 2021-03-30
IL276170B2 (en) 2025-03-01
DK3746467T3 (da) 2026-01-12
SI3746467T1 (sl) 2026-02-27
AU2019214358B2 (en) 2023-05-25
PT3746467T (pt) 2026-01-13
RS67606B1 (sr) 2026-01-30
SG11202006903WA (en) 2020-08-28
NZ766762A (en) 2026-03-27
US20210292387A1 (en) 2021-09-23
CN111770934A (zh) 2020-10-13
EP3746467A1 (en) 2020-12-09
CA3089657A1 (en) 2019-08-08
FI3746467T3 (fi) 2026-01-16
RU2020126210A (ru) 2022-02-28
LT3746467T (lt) 2026-01-26
CO2020008308A2 (es) 2020-10-30
PH12020551118A1 (en) 2021-07-05
MY199821A (en) 2023-11-23
PL3746467T3 (pl) 2026-04-13
MA52994A (fr) 2021-05-05
US20240218042A1 (en) 2024-07-04
AU2019214358A1 (en) 2020-08-20
IL276170A (en) 2020-09-30
AR114325A1 (es) 2020-08-19
US11725036B2 (en) 2023-08-15
HRP20260016T1 (hr) 2026-02-27
MX2020008096A (es) 2020-09-24
EP3746467B1 (en) 2025-10-08
JP2021512099A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
TWI763972B (zh) 經修飾之脂質化鬆弛素ｂ鏈胜肽及其醫療用途
US10988523B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
CN111491658A (zh) 肠促胰岛素类似物及其用途
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
US10988524B2 (en) Modified relaxin B chain peptides and their therapeutic use
WO2023161229A1 (en) Crf2 receptor agonists and their use in therapy
EP4658674A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
RU2804702C2 (ru) Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
CN118510796A (zh) 用于治疗肾脏病症或疾患的松弛素和加压素类似物的组合
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy